CTRI/2024/03/064428尚未招募2 期
Weekly bortezomib-dexamethasone as a third-line therapy for patients with warm autoimmune hemolytic anemia - NI
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Adult patients 18 to 60 years of age and of either sex diagnosed with wAIHA (idiopathic, or secondary to an autoimmune disorder) who are relapsed, or refractory (RR) to prednisolone and single agent rituximab as first and second-line therapies, respectively and require initiation of third-line treatment will be included.
排除标准
- •Patients with wAIHA less than 18 years of age, wAIHA secondary to a lymphoproliferative disorder and those unwilling to participate in the study will be excluded
研究者
相似试验
已完成
2 期
Weekly bortezomib + dexamethasone therapy for elderly patients with relapsed or refractory multiple myeloma (A multicenter clinical phase II trial, JMSG-0902)Multiple myelomaJPRN-UMIN000003345Japan myeloma study group50
进行中（未招募）
不适用
Bortezomib-Doxorubicin-Dexamethasone (BDD) as Treatment for Patients with Multiple Myeloma Presenting with Acute Renal Failure - BDDThe occurrence of renal failure is an emergency situation in patients with multiple myeloma. A fast active relatively, non-toxic protocol seems presently the best option for attempts to reverse renal insufficiency. Therefore we have designed a small Phase 2 trial with a Bortezomib containing regimen, which intends to revert renal failure in a greater proportion of patients compared to conventional regimens.EUCTR2005-003001-85-CZAustrian Forum against Cancer50
进行中（未招募）
1 期
Bortezomib-Doxorubicin-Dexamethasone (BDD) as Treatment for Patients with Multiple Myeloma Presenting with Acute Renal Failure - BDDThe occurrence of renal failure is an emergency situation in patients with multiple myeloma. A fast active relatively, non-toxic protocol seems presently the best option for attempts to reverse renal insufficiency. Therefore we have designed a small Phase 2 trial with a Bortezomib containing regimen, which intends to revert renal failure in a greater proportion of patients compared to conventional regimens.EUCTR2005-003001-85-ATAustrian Forum against Cancer50
进行中（未招募）
1 期
Bortezomib-Doxorubicin-Dexamethasone (BDD) as Treatment for Patients with Multiple Myeloma Presenting with Acute Renal Failure - BDDEUCTR2005-003001-85-SKAustrian Forum against Cancer50
进行中（未招募）
1 期
Bortezomib-Doxorubicin-Dexamethasone (BDD) as Treatment for Patients with Multiple Myeloma Presenting with Acute Renal Failure - BDDThe occurrence of renal failure is an emergency situation in patients with multiple myeloma. A fast active relatively, non-toxic protocol seems presently the best option for attempts to reverse renal insufficiency. Therefore we have designed a small Phase 2 trial with a Bortezomib containing regimen, which intends to revert renal failure in a greater proportion of patients compared to conventional regimens.EUCTR2005-003001-85-HUAustrian Forum against Cancer50